OptiCor, a cutting-edge Clinical Decision Support Software, leads the way in cardiovascular care by seamlessly incorporating the latest 2023 ACC/AHA Guideline for Atrial Fibrillation. With a validated risk prediction algorithm, OptiCor empowers healthcare professionals with individualized stroke risk assessments, navigating away from the conventional CHA2DS2-VASc scoring system. This paradigm shift aligns perfectly with the guideline's emphasis on personalized therapy decisions, resulting in a significant reduction in mortality, stroke, and bleeding compared to standard care. The user-friendly interface and EHR integration of the enhanced version position OptiCor as the exclusive solution for implementing the new guideline, reinforcing its commitment to shaping the future of cardiovascular care through evidence-based precision and innovation.

tenacio transforms cardiovascular care by using individual risk prediction and curated treatment recommendations which help health care providers to provide efficient care and optimal treatments for patients, resulting in better outcomes and lower cost.

• eCART is a research-based, AI-driven software as a medical device (SaMD) that utilizes a machine learning algorithm to continuously assess hospitalized patients’ risk of impending death or intensive care unit (ICU) transfer, assisting medical staff in swift and accurate recognition of patients requiring increased medical attention. eCART draws upon readily available patient data from the EHR, rapidly quantifies disease severity, and predicts likelihood of critical illness onset, hours before it happens.
• eCART received FDA 510(k) clearance in 2024, with clinical performance data of nearly two million hospitalizations from 21 hospitals, including an unprecedented level of real-world prospective data, to ensure consistent accuracy across geography, age, race, and top medical conditions (e.g. sepsis, COPD, heart failure). 
• Built upon more than a decade of ongoing scientific research, eCART was developed at UChicago Medicine by Dr. Dana Edelson, MD, MS and Dr. Matthew Churpek, MD, PhD and is well chronicled in published literature. The analytic and workflow have been in use in clinical practice since 2016.

At AgileMD, we are building the most advanced real-time predictive analytics and clinical pathways platform for hospitals.

To date, AgileMD tools have been used on more than 4 million patient encounters by more than 135,000 clinical users in over 250 hospitals, including some of the nation's leading academic medical centers. AgileMD's eCART clinical deterioration prediction software is FDA cleared and the first AI-powered early warning device for ward patients to go through the FDA process with real-world prospective data. 

AgileMD is backed by premier start-up partners MATTER, YCombinator, and Rock Health, and our cutting-edge analytics are built on more than decade of ongoing research at the University of Chicago. In 2021, AgileMD garnered nearly $3 million in combined federal research and development funding from the U.S. Department of Health and Human Services (HHS), including the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA).

OptiCor is the only Clinical Decision Support which incorporates the 2023 ACC/AHA AF Guideline because it provides precise treatment decisions based on individual stroke risk prediction.

Its focus is on proven outcome improvements and a superior user experience, making it easier and faster for HCPs to identify the optimal treatment for a patient. 

• Only CDS which supports the new 2023 ACC/AHA AF treatment paradigm
• Proven outcome benefits and cost savings
• Superior user experience
• FDA reviewed, proprietary and validated risk prediction algorithm

• Continuously monitors EHR data in real time
• Stratifies hospitalized patients by risk of impending all-cause clinical deterioration and sepsis
• Notifies inpatient providers when patient may need additional assessment and management
• Recommends clinical pathways with integrated order entry

• Authorized: FDA 510(k) cleared
• Tested: Derived and validated in nearly 3 million patient encounters across 28 hospitals
• Experienced: 8+ years in clinical use; 10+ years of published academic literature on value over other early warning scores
• Accurate: High sensitiviy and specificity, meaning fewer false alarms and more efficient focus on the highest risk patients
• Integrated: Embedded cross-team workflow ensures that risk scores are not ignored and action is taken
• Benchmarked: Robust reporting, benchmarking, and implementation support drive quality improvement